Artiva Biotherapeutics, Inc. (ARTV) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 39 institutional investors hold a position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV).

• Artiva Biotherapeutics saw its institutional ownership percentage rose to 74.0% in September 2025 from 31.0% in June 2025.
• Quarterly data indicates a 3.65% shift in institutional share volume, and the annual owner count reflects a decrease of 22.00%.
• Of these 39 institutional investors, 13 increased their holdings in Artiva Biotherapeutics, while 16 of them reduced positions, and 10 investors maintained their exposure.
• The total number of shares held by institutions in Artiva Biotherapeutics increased to 18.10Mn as of September 2025, a net change of up by 637.24K shares quarter on quarter, and down 2.62Mn shares year over year.
• RA CAPITAL MANAGEMENT, L.P. continues to be the largest institutional holder of Artiva Biotherapeutics as of September 30, 2025, with a position of 9.85Mn shares, representing 40.28% of the company's outstanding stock.
• Among the most significant buyers of Artiva Biotherapeutics during September 2025 were CITADEL ADVISORS LLC (798.40K), BNP PARIBAS FINANCIAL MARKETS (117.73K), CITIGROUP INC (102.01K), RENAISSANCE TECHNOLOGIES LLC (79.15K), LANDSCAPE CAPITAL MANAGEMENT, L.L.C. (39.13K).
• Leading sellers of Artiva Biotherapeutics stock in September 2025 included BlackRock, Inc. (191.31K), VANGUARD GROUP INC (73.85K), GOLDMAN SACHS GROUP INC (68.23K), MILLENNIUM MANAGEMENT LLC (64.91K), HRT FINANCIAL LP (50.70K).
• The top 10 institutional holders of Artiva Biotherapeutics for the quarter ending September 2025 included RA CAPITAL MANAGEMENT, L.P. (9.85Mn), 5AM Venture Management, LLC (2.35Mn), VR Adviser, LLC (1.61Mn), venBio Partners LLC (1.15Mn), CITADEL ADVISORS LLC (798.40K), FRANKLIN RESOURCES INC (520.33K), BlackRock, Inc. (294.42K), MILLENNIUM MANAGEMENT LLC (262.16K), WELLINGTON MANAGEMENT GROUP LLP (194.11K), VANGUARD GROUP INC (159.12K).